DCM
CBIO

Dupont Capital Management’s Crescent Biopharma CBIO Stock Holding History

Dupont Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-619
Closed -$190K – 1343
2020
Q3 		$190K Buy
+619
New +$237K ﹤0.01% 1127

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dupont Capital Management's CBIO Position: Q4 2020 in Review

Dupont Capital Management sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 619 shares — an estimated $190K sold.

Dupont Capital Management first reported a position in CBIO in Q3 2020 and held it in 1 quarter. The position peaked at $190K in Q3 2020. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

  • Dupont Capital Management reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
  • Dupont Capital Management sold 619 Crescent Biopharma shares in Q4 2020, an estimated $190K.
  • Dupont Capital Management first reported a position in Crescent Biopharma in Q3 2020 and held it in 1 quarter.
  • Dupont Capital Management's Crescent Biopharma position peaked at $190K in Q3 2020.
  • 89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on Dupont Capital Management's 13F filing for Q4 2020, filed 28 Jan 2021.